NASDAQ:ARWR Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis $28.19 -0.75 (-2.59%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$28.12▼$29.6050-Day Range$22.78▼$29.5452-Week Range$20.67▼$39.83Volume847,114 shsAverage Volume1.28 million shsMarket Capitalization$3.50 billionP/E RatioN/ADividend YieldN/APrice Target$43.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Arrowhead Pharmaceuticals alerts: Email Address Arrowhead Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside53.4% Upside$43.25 Price TargetShort InterestBearish7.28% of Shares Sold ShortDividend StrengthN/ASustainability-2.55Upright™ Environmental ScoreNews Sentiment0.61Based on 18 Articles This WeekInsider TradingSelling Shares$279,415 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.04) to ($2.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.17 out of 5 starsMedical Sector179th out of 936 stocksPharmaceutical Preparations Industry74th out of 436 stocks 4.3 Analyst's Opinion Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageArrowhead Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arrowhead Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.28% of the outstanding shares of Arrowhead Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently increased by 1.57%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArrowhead Pharmaceuticals has received a 39.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Cardiovascular siRNA medication", "RNA interference medication for cancer", and "Liver-disease medication (A05)" products. See details.Environmental SustainabilityThe Environmental Impact score for Arrowhead Pharmaceuticals is -2.55. Previous Next 2.0 News and Social Media Coverage News SentimentArrowhead Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Arrowhead Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for ARWR on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $279,415.00 in company stock.Percentage Held by InsidersOnly 4.50% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arrowhead Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to grow in the coming year, from ($3.04) to ($2.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is -6.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is -6.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 10.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arrowhead Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Awesomely, LLCAutomatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…Watch this short video About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR)Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Read More ARWR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARWR Stock News HeadlinesJuly 4, 2024 | insidertrades.comTracie Oliver Sells 9,394 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) StockJuly 26 at 4:09 PM | seekingalpha.comArrowhead Pharmaceuticals: Driving To CommercializationJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 26 at 3:44 AM | americanbankingnews.comEquities Analysts Set Expectations for Arrowhead Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:ARWR)July 24 at 11:23 AM | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)July 24 at 10:54 AM | finance.yahoo.comArrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter ResultsJuly 23 at 7:49 PM | markets.businessinsider.comBuy Rating Affirmed: Arrowhead Pharmaceuticals’ Advancements in RNAi Pulmonary Therapeutics Signal Market Growth PotentialJuly 20, 2024 | americanbankingnews.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 19, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)July 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arrowhead Pharmaceuticals on Promising Asthma Drug Prospects and Market Expansion PotentialJuly 19, 2024 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Rating Reiterated by Chardan CapitalJuly 17, 2024 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to "Sell" at StockNews.comJuly 16, 2024 | americanbankingnews.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Short Interest Down 5.8% in JuneJune 25, 2024 | businesswire.comCanva Upskills 70 Million Educators and Students Globally with New Teacher Certification CourseJune 25, 2024 | businesswire.comArrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes TrialMay 31, 2024 | businesswire.comArrowhead Pharmaceuticals to Participate in Upcoming June 2024 ConferencesMay 29, 2024 | businesswire.comArrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed HyperlipidemiaSee More Headlines Receive ARWR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARWR CUSIPN/A CIK879407 Webwww.arrowheadpharma.com Phone(626) 304-3400Fax626-304-3401Employees525Year FoundedN/APrice Target and Rating Average Stock Price Target$43.25 High Stock Price Target$60.00 Low Stock Price Target$27.00 Potential Upside/Downside+52.7%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-205,270,000.00 Net Margins-163.32% Pretax Margin-1,347.67% Return on Equity-140.72% Return on Assets-59.92% Debt Debt-to-Equity RatioN/A Current Ratio8.31 Quick Ratio8.31 Sales & Book Value Annual Sales$240.74 million Price / Sales14.62 Cash FlowN/A Price / Cash FlowN/A Book Value$2.68 per share Price / Book10.57Miscellaneous Outstanding Shares124,200,000Free Float118,611,000Market Cap$3.52 billion OptionableOptionable Beta0.94 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Christopher R. Anzalone Ph.D. (Age 55)CEO, President & Director Comp: $1.6MMr. Kenneth A. Myszkowski (Age 58)Chief Financial Officer Comp: $834.34kMr. Patrick O'Brien J.D. (Age 60)PharmD, COO, General Counsel & Secretary Comp: $835.14kDr. James C. Hamilton M.D. (Age 46)MBA, Chief of Discovery & Translational Medicine Comp: $762.14kDr. Mark M. Davis Ph.D.Founder and Founder & Director of Insert Therapeutics Inc & CalandoDr. Vincent Anzalone CFAHead of Investor Relations & VPMr. Howard LovyDirector of CommunicationsDr. Bruce D. Given M.D. (Age 70)Chief Medical Scientist Comp: $486.31kDr. Mark Seefeld (Age 70)Head of Toxicology & VP Ms. Tracie Oliver (Age 62)Chief Commercial Officer Comp: $449.58kMore ExecutivesKey CompetitorsBausch Health CompaniesNYSE:BHCSarepta TherapeuticsNASDAQ:SRPTDr. Reddy's LaboratoriesNYSE:RDYInsmedNASDAQ:INSMLegend BiotechNASDAQ:LEGNView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 30,086 shares on 7/26/2024Ownership: 0.874%EFG Asset Management North America Corp.Bought 24,083 shares on 7/26/2024Ownership: 0.042%State of Michigan Retirement SystemSold 600 shares on 7/26/2024Ownership: 0.024%Banque Pictet & Cie SASold 3,261 shares on 7/25/2024Ownership: 0.084%Louisiana State Employees Retirement SystemSold 600 shares on 7/24/2024Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions ARWR Stock Analysis - Frequently Asked Questions How have ARWR shares performed this year? Arrowhead Pharmaceuticals' stock was trading at $30.60 on January 1st, 2024. Since then, ARWR shares have decreased by 7.9% and is now trading at $28.19. View the best growth stocks for 2024 here. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) issued its earnings results on Thursday, May, 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.96. The firm's revenue for the quarter was down 100.0% compared to the same quarter last year. Who are Arrowhead Pharmaceuticals' major shareholders? Top institutional shareholders of Arrowhead Pharmaceuticals include Bank of New York Mellon Corp (0.87%), Retirement Systems of Alabama (0.12%), Banque Pictet & Cie SA (0.08%) and Assenagon Asset Management S.A. (0.07%). Insiders that own company stock include Christopher Richard Anzalone, Patrick O'brien, Kenneth Allen Myszkowski, James C Hamilton, Martin Javier San, Douglas B Given, Tracie Oliver, Hongbo Lu, Victoria Vakiener, William D Waddill and Adeoye Y Olukotun. View institutional ownership trends. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP) and Bank of America (BAC). This page (NASDAQ:ARWR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARWR Stock Alerts